News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Mario Balsa: A PI3K Path Worth Walking – If You Can Manage the Steps
Mario Balsa/X
Jul 13, 2025, 13:57

Mario Balsa: A PI3K Path Worth Walking – If You Can Manage the Steps

Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology (ICO), shared a post on X:

“INAVO120 (NEJM): In PIK3CA-mutated, HR+/HER2– endocrine-resistant MBC, inavolisib + palbociclib + fulvestrant vs placebo:

  • mOS: 34.0 vs 27.0 mo (HR 0.67; p=0.02)
  • Higher AEs: 6.8% d/c due to toxicity

A PI3K path worth walking – if you can manage the steps.

Congrats to Komal Jhaveri and all the team!”

Title: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

Journal: NEJM

Authors: Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner

Read the full article.

Mario Balsa

More posts featuring Mario Balsa on OncoDaily.

cancer Catalan Institute of Oncology Chunyan Song Cristina Saura Dejan Juric Eirini Thanopoulou Fulvestrant ICO INAVO120 Inavolisib Kevin Kalinsky Komal Jhaveri Komal L. Jhaveri Mario Balsa Nicholas C. Turner Noopur Shankar OncoDaily Oncology palbociclib Peter Schmid PIK3CA-mutated breast cancer Seock-Ah Im Sherene Loi Sibylle Loibl Thomas J Stout Tiffany D. Clark Yanling Jin
Special Coverage
Insight
Aug 24, 2025, 07:13
Olivier Elemento: AI in Hematology - A 2025 Snapshot from ASH
Insight
Aug 24, 2025, 07:09
Arturo LoAIza-Bonilla: Co-Authoring Insights on Large Language Models in Radiation Oncology
Drugs
Aug 24, 2025, 05:59
Lonsurf (Trifluridine/Tipiracil): A Patient’s Guide 2025 to Treatment for Advanced Colorectal and Stomach Cancer
Drugs
Aug 24, 2025, 05:22
Lonsurf (trifluridine/tipiracil) 2025 Updates: Uses in Cancer, Side Effects, Dosage, Expectations, and More
Blog Posts
Aug 24, 2025, 05:05
Naveen Pemmaraju: Wonderful to Meet Friends and Colleagues at MPN meeting 2025
Insight
Aug 24, 2025, 04:55
Shilpa Gupta Shared Highlights from IBCG 2025
Voices
Aug 24, 2025, 03:00
Giuseppe Minniti: Gliofocus Phase 3 Trial Explores PARP Inhibitors with Radiotherapy in GBM
Voices
Aug 24, 2025, 01:32
Minhua Chu: Zelgen Biopharma’s ZGGS34 Gets FDA Approval for Solid Tumor Study
Insight
Aug 24, 2025, 01:13
Discovering Approaches to Enhance CAR-NK Cell Antitumor Activity with CRISPR - MD Anderson Cancer Center
Voices
Aug 23, 2025, 23:27
Lauren Kriger Groner: Filming the Cracking Cancer Podcast with The White Ribbon Project
Voices
Aug 23, 2025, 22:57
Paolo Tarantino: Exploring IO and ADC Combinations at SITC25
Drugs
Aug 23, 2025, 22:35
LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen